TW200745162A - Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 - Google Patents

Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38

Info

Publication number
TW200745162A
TW200745162A TW095118554A TW95118554A TW200745162A TW 200745162 A TW200745162 A TW 200745162A TW 095118554 A TW095118554 A TW 095118554A TW 95118554 A TW95118554 A TW 95118554A TW 200745162 A TW200745162 A TW 200745162A
Authority
TW
Taiwan
Prior art keywords
antibodies
human
profiling
generation
antibodies specific
Prior art date
Application number
TW095118554A
Other languages
English (en)
Inventor
Michael Tesar
Robert Friesen
Stefan Steidl
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of TW200745162A publication Critical patent/TW200745162A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW095118554A 2005-05-24 2006-05-24 Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38 TW200745162A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68377205P 2005-05-24 2005-05-24
US70600405P 2005-08-08 2005-08-08

Publications (1)

Publication Number Publication Date
TW200745162A true TW200745162A (en) 2007-12-16

Family

ID=37184002

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095118554A TW200745162A (en) 2005-05-24 2006-05-24 Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38

Country Status (5)

Country Link
US (1) US20090123950A1 (zh)
EP (2) EP2799451A1 (zh)
AR (1) AR053489A1 (zh)
TW (1) TW200745162A (zh)
WO (1) WO2006125640A2 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI564304B (zh) * 2010-12-30 2017-01-01 武田藥品工業有限公司 抗ｃｄ３８抗體

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2511297T1 (sl) 2004-02-06 2015-07-31 Morphosys Ag Proti -CD38 humana protitelesa in njihova uporaba
ES2541489T3 (es) 2004-02-06 2015-07-21 Morphosys Ag Anticuerpos humanos anti-CD38 y usos para ellos
US9200061B2 (en) * 2004-02-06 2015-12-01 Morpho Sys AG Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i
CN107033243B (zh) 2005-03-23 2020-12-15 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
EP1945671A2 (en) * 2005-10-12 2008-07-23 MorphoSys AG Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
PL2081595T3 (pl) 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
UY32317A (es) 2008-12-12 2010-07-30 Boehringer Ingelheim Int Anticuerpos anti-igf
JP6093696B2 (ja) * 2010-06-09 2017-03-08 ゲンマブ エー／エス ヒトｃｄ３８に対する抗体
ES2617446T3 (es) 2010-09-27 2017-06-19 Morphosys Ag Anticuerpo anti-cd38 y lenalidomida o bortezomib para el tratamiento del mieloma múltiple y nhl
SG11201401518TA (en) 2011-10-28 2014-05-29 Teva Pharmaceuticals Australia Pty Ltd Polypeptide constructs and uses thereof
PT2900232T (pt) 2012-09-25 2018-02-09 Morphosys Ag Combinações e suas utilizações
WO2014068114A1 (en) 2012-11-05 2014-05-08 Morphosys Ag Radiolabelled antibody and uses thereof
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
US11117975B2 (en) 2013-04-29 2021-09-14 Teva Pharmaceuticals Australia Pty Ltd Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
PT2992013T (pt) 2013-04-29 2020-03-05 Teva Pharmaceuticals Australia Pty Ltd Anticorpos anti-cd38 e fusões a interferão alfa-2b atenuado
CN105579058A (zh) * 2013-07-15 2016-05-11 小利兰·斯坦福大学托管委员会 Cd38激动剂的医学用途
JP2016536314A (ja) * 2013-10-31 2016-11-24 サノフイ ヒトのがんを治療するための特異的抗ｃｄ３８抗体
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
WO2016040294A2 (en) 2014-09-09 2016-03-17 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
CA2965414C (en) 2014-10-29 2024-01-09 Teva Pharmaceuticals Australia Pty Ltd Interferon .alpha.2.beta. variants
NZ732753A (en) 2014-12-04 2024-08-30 Janssen Biotech Inc Anti-cd38 antibodies for treatment of acute myeloid leukemia
HUE054271T2 (hu) 2015-05-13 2021-08-30 Morphosys Ag Mielóma Multiplex (MM) kezelése
KR102602754B1 (ko) 2015-05-20 2023-11-14 얀센 바이오테크 인코포레이티드 경쇄 아밀로이드증 및 다른 cd38-양성 혈액학적 악성종양을 치료하기 위한 항-cd38 항체
ES2890783T3 (es) 2015-06-22 2022-01-24 Janssen Biotech Inc Terapias de combinación para enfermedades malignas hematológicas con anticuerpos anti-CD38 e inhibidores de survivina
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
FI3313441T3 (fi) 2015-06-24 2024-03-28 Janssen Biotech Inc Kiinteiden kasvainten immunomodulaatio ja hoito spesifisesti cd38:aa sitovilla vasta-aineilla
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
CN108472369A (zh) 2015-11-03 2018-08-31 詹森生物科技公司 抗cd38抗体的皮下制剂及其用途
CA3016098A1 (en) 2016-03-04 2017-09-08 Morphosys Ag Clinical assessment of m-protein response in multiple myeloma
US20190233533A1 (en) 2016-06-28 2019-08-01 Umc Utrecht Holding B.V. Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
EP3484923A1 (en) 2016-07-15 2019-05-22 Takeda Pharmaceutical Company Limited Methods and materials for assessing response to plasmablast- and plasma cell-depleting therapies
CN117717604A (zh) 2016-07-19 2024-03-19 梯瓦制药澳大利亚股份有限公司 抗cd47联合治疗
EP3487506A1 (en) 2016-07-20 2019-05-29 Hybrigenics SA Combinations of inecalcitol with an anti-cd38 agent and their uses for treating cancer
US20230103584A1 (en) * 2017-06-08 2023-04-06 Black Belt Therapeutics Limited Cd38 modulating antibody agents
WO2018224682A1 (en) * 2017-06-08 2018-12-13 Tusk Therapeutics Ltd Cd38 modulating antibody
SG11202000484TA (en) 2017-08-16 2020-02-27 Black Belt Therapeutics Ltd Cd38 antibody
AU2018316521A1 (en) * 2017-08-16 2020-02-13 Black Belt Therapeutics Limited CD38 modulating antibody
US11542338B2 (en) 2017-08-16 2023-01-03 Black Belt Therapeutics Limited CD38 modulating antibody
MA50514A (fr) 2017-10-31 2020-09-09 Janssen Biotech Inc Méthodes de traitement du myélome multiple à haut risque
MX2020007429A (es) 2018-01-12 2020-10-15 Takeda Pharmaceuticals Co Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).
WO2019149743A1 (en) 2018-01-30 2019-08-08 Cellectis Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen
US20210047427A1 (en) 2018-03-28 2021-02-18 Takeda Pharmaceutical Company Limited Subcutaneous dosing of anti-cd38 antibodies
CN108752475B (zh) * 2018-06-14 2021-07-30 北京智仁美博生物科技有限公司 抗人cd38抗体及其用途
EP3867275A2 (en) 2018-10-17 2021-08-25 Janssen Biotech, Inc. Method of providing subcutaneous administration of anti-cd38 antibodies
WO2020120730A1 (en) 2018-12-14 2020-06-18 Morphosys Ag Antibody formulations
KR20220002891A (ko) 2019-03-15 2022-01-07 모르포시스 아게 자가항체-매개 자가면역 질병의 치료를 위한 항-cd38 항체 및 이의 약제학적 조성물
AR120054A1 (es) 2019-06-10 2022-02-02 Takeda Pharmaceuticals Co Politerapias con anticuerpos de cd-38
CA3173257A1 (en) 2020-02-26 2021-09-02 Biograph 55, Inc. C19 c38 bispecific antibodies
WO2022152823A1 (en) 2021-01-14 2022-07-21 Morphosys Ag Anti-cd38 antibodies and their uses
US20220275090A1 (en) 2021-02-22 2022-09-01 Janssen Biotech, Inc. Combination Therapies with Anti-CD38 Antibodies and PARP or Adenosine Receptor Inhibitors
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療
CA3237175A1 (en) 2021-11-03 2023-05-11 Janssen Biotech, Inc. Corticosteriod reduction in treatment with anti-cd38 antibodies
WO2023144303A1 (en) 2022-01-31 2023-08-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Cd38 as a biomarker and biotarget in t-cell lymphomas
WO2024147934A1 (en) 2023-01-06 2024-07-11 Takeda Pharmaceutical Company Limited Anti-cd38 antibodies for the treatment of autoimmune diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
GB9424449D0 (en) * 1994-12-02 1995-01-18 Wellcome Found Antibodies
US20020164788A1 (en) * 1994-12-02 2002-11-07 The Wellcome Foundation Limited Humanized antibodies to CD38
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
CA2329940A1 (en) * 1998-06-05 1999-12-09 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to cd38 to treat multiple myeloma
US7223397B1 (en) * 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
WO2001005950A2 (en) 1999-07-20 2001-01-25 Morphosys Ag Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
EP1174440A1 (en) * 2000-07-19 2002-01-23 U-BISys B.V. A selectively-expressed epitope on the human CD38 molecule detected by a phage display library-derived human scFv antibody fragment
JP4406206B2 (ja) * 2001-04-24 2010-01-27 バイエル コーポレーション ヒトｔｉｍｐ−１抗体
US7084257B2 (en) * 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US7262278B2 (en) * 2001-10-15 2007-08-28 Kirin Beer Kabushiki Kaisha Anti-HLA-DR antibody
CA2542840A1 (en) * 2003-10-22 2005-05-12 University Of Rochester Anti-thymocyte antiserum and use thereof to trigger b cell apoptosis

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI564304B (zh) * 2010-12-30 2017-01-01 武田藥品工業有限公司 抗ｃｄ３８抗體

Also Published As

Publication number Publication date
WO2006125640A2 (en) 2006-11-30
EP2799451A1 (en) 2014-11-05
WO2006125640A3 (en) 2007-04-12
AR053489A1 (es) 2007-05-09
US20090123950A1 (en) 2009-05-14
EP1888647A2 (en) 2008-02-20

Similar Documents

Publication Publication Date Title
TW200730624A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
TW200745162A (en) Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
PH12015500248A1 (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
MX2010004219A (es) Agentes de enlace de cd19 y usos de los mismos.
WO2012034116A3 (en) Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
MX2020000342A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos.
JO3097B1 (ar) الأجسام المضادة c-Met
TN2012000555A1 (en) Antibodies to human gdf8
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
AU2016219704A1 (en) Anti-Notch1 antibodies
EA200970874A1 (ru) Антитела против склеростина
TW200736275A (en) Methods and compositions for treating allergic diseases
NO20063986L (no) Anti-CD-38-humane antistoffer og anvendelse derav
TN2009000529A1 (en) Methods and compositions for treating allergic diseases
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
HK1102626A1 (en) Compositions and methods for the treatment and prevention of hyperproliferative diseases
MX2010004814A (es) Metodos para tratar esclerodermia.
ATE445408T1 (de) Verwendung von prolactin in der prophylaktischen krebstherapie
EA202092640A1 (ru) Способы и композиции для лечения хронической крапивницы
AU2014256372B2 (en) New compositions for treating CMT and related disorders
UA104739C2 (en) c-MET ANTIBODIES
UA112521C2 (uk) Антитіло проти gdf8 людини